Prions cause fatal neurodegenerative conditions such as scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in humans^[@R1]^. The fundamental molecular process, seeded propagation of assemblies of misfolded host protein, is increasingly recognised as being of importance in all the major human neurodegenerative diseases^[@R3]^. There is a common polymorphism, present worldwide, in the substrate protein in human prion disease, human prion protein (PrP), where either methionine (M) or valine (V) is present at residue 129. MV heterozygosity provides relative protection against acquired, sporadic, and some inherited prion diseases^[@R4]-[@R6]^ and may have been selected during the evolution of modern humans by ancestral prion disease epidemics^[@R7]^. This protective effect is thought to relate to inhibition of homotypic protein-protein interactions^[@R5],\ [@R8]^ although residue 129 also influences the propagation of particular prion strains via conformational selection^[@R9],\ [@R10]^. Heterozygosity at another polymorphism, E219K, also provides resistance to CJD in Japan^[@R11]^.

Kuru was a devastating epidemic prion disease transmitted by endocannibalism and restricted to a remote area in Papua New Guinea (PNG). We reported a novel PrP variant (G127V) amongst unaffected individuals which appeared be a resistance factor selected by the epidemic and unique to this region^[@R2]^. Given the proximity to residue 129, we considered that it may have a similar action to M129V, blocking homotypic interactions and exerting its protective effect only in the heterozygous state. No *PRNP* codon 127VV homozygotes were identified in the kuru-exposed population and V^127^ was always seen on an M^129^ allele^[@R2]^. We therefore generated multiple lines of transgenic mice, expressing only human PrP (HuPrP) on a congenic FVB/N *Prnp*^o/o^ background, to investigate whether G127V was indeed protective and whether this protection was dependent on heterozygosity or was an intrinsic property of the variant protein. Additionally we investigated its interaction with the residue 129 polymorphism.

Two lines of transgenic mice homozygous for HuPrP V^127^ were studied: Tg(HuPrP V^127^M^129^/V^127^M^129^ *Prnp^o/o^*)-183 (V^127^M^129^ Tg183) and Tg(HuPrP V^127^M^129^/V^127^M^129^ *Prnp^o/o^*)-190 (V^127^M^129^ Tg190). PrP expression levels in homozygotes as compared to pooled normal human brain were 2-fold for V^127^M^129^ Tg183 and 1-fold for V^127^M^129^ Tg190. G127V heterozygous mice were derived by crossing these lines with FVB-congenic versions of Tg35 mice homozygous for HuPrP G^127^M^129^ ^[@R12]-[@R15]^ or Tg152 mice homozygous for HuPrP G^127^V^129^ ^[@R15]-[@R19]^ designated Tg(HuPrP G^127^M^129^/G^127^M^129^ *Prnp^o/o^*)-35c (G^127^M^129^ Tg35c) and Tg(HuPrP G^127^V^129^/G^127^V^129^ *Prnp^o/o^*)-152c (G^127^V^129^ Tg152c) respectively. G^127^M^129^ Tg35c and G^127^V^129^ Tg152c express wild type huPrP at 2- and 6-times respectively as compared to pooled normal human brain ([table 1](#T1){ref-type="table"}). [Extended Data Fig.1](#F2){ref-type="fig"} shows relative PrP^C^ expression levels in all transgenic mice used in this study.

All transgenic lines were then challenged by intracerebral prion inoculation from well-characterised and previously transmitted human prion disease cases including all three *PRNP* codon 129 genotypes and comprising four cases of kuru, 12 cases of classical CJD and two cases of variant CJD (vCJD). Heterozygous HuPrP G^127^M^129^/V^127^M^129^ mice (Tg35c × Tg183 and Tg35c × Tg190) ([table 1](#T1){ref-type="table"}), having the genotype associated with disease resistance in the kuru-exposed human population, proved completely resistant to all four kuru isolates (which included all three *PRNP* codon 129 genotypes and two molecular strain types) ([Fig. 1a](#F1){ref-type="fig"} and [table 2a](#T2){ref-type="table"}) while mice expressing wild type HuPrP G^127^M^129^/G^127^M^129^ (Tg35c) ([Fig. 1a](#F1){ref-type="fig"}, [table 2a](#T2){ref-type="table"}) or G^127^V^129^/G^127^V^129^ (Tg152c) ([table 2b](#T2){ref-type="table"}) were fully susceptible with 100% attack rates. This is consistent with the population genetic data suggesting kuru resistance of G127V individuals. We have previously reported that prion strains seen in kuru brain are indistinguishable from those seen in classical CJD patients^[@R19]^. Similarly, none of four classical CJD isolates from patients of *PRNP* genotype 129MM transmitted to either line of G^127^M^129^/V^127^M^129^ mice ([table 2a](#T2){ref-type="table"} and [Fig. 1b](#F1){ref-type="fig"}), while all four transmitted uniformly to Tg35c mice expressing wild type huPrP ([Fig. 1b](#F1){ref-type="fig"} and [table 2a](#T2){ref-type="table"}). Remarkably, however, occasional G^127^M^129^/V^127^M^129^ mice developed clinical disease, and a larger number showed evidence of subclinical infection (positive PrP immunohistochemistry and/or western blot for PrP^Sc^), on challenge with vCJD prions ([table 2d](#T2){ref-type="table"} and [Extended Data Fig. 2](#F3){ref-type="fig"}). vCJD is a novel BSE-derived prion strain^[@R17],\ [@R20],\ [@R21]^ to which the population in the kuru-affected area of PNG were not exposed.

The key question with respect to whether the protective effect of V^127^ is via a similar mechanism to the M129V polymorphism was addressed by challenge of mice homozygous for HuPrP V^127^M^129^. While mice homozygous for wild type HuPrP G^127^M^129^ or G^127^V^129^ are both highly susceptible to CJD prions, remarkably mice homozygous for HuPrP V^127^M^129^ were completely resistant to all 18 human prion disease isolates, including vCJD prions, with no clinical transmissions or evidence of subclinical infection ([Fig. 1a and b](#F1){ref-type="fig"}, [table 3](#T3){ref-type="table"} and [Extended Data Fig. 3](#F4){ref-type="fig"}).

We also challenged mice heterozygous at both residues 127 and 129 of HuPrP (G^127^V^129^/V^127^M^129^) produced by crossing Tg183 or Tg190 mice with Tg152c mice ([tables 1](#T1){ref-type="table"} and [2B](#T2){ref-type="table"}). The higher level of expression of HuPrP V^129^ in Tg152c mice as compared to the other lines meant that there was a marked difference in the ratio of expression of the variant (V^127^M^129^) and wild type (G^127^V^129^) HuPrP in these crosses ([table 1](#T1){ref-type="table"}). While Tg183 and Tg35c had closely similar levels of expression of V^127^M^129^ and G^127^M^129^ HuPrP respectively, such that the Tg35c × Tg183 cross closely modelled the human *PRNP* G127V genotype, the expression ratios of wild type G^127^V^129^ to variant V^127^M^129^ HuPrP were approximately 6:1 and 3:1 for the Tg152c × Tg190 and Tg152c × Tg183 crosses respectively ([table 1](#T1){ref-type="table"}, [Extended Data Fig.1](#F2){ref-type="fig"} and [4](#F5){ref-type="fig"}). Interestingly, in these crosses some transmissions of kuru and classical CJD prions were seen ([table 2b](#T2){ref-type="table"}, [Extended Data Fig. 4](#F5){ref-type="fig"} and [5](#F6){ref-type="fig"}). In the Tg152c × Tg183 crosses, with a 3-fold excess of wild type PrP, subclinical infections were seen with four out of the 12 isolates used, and one kuru isolate (I10336) was associated with clinical disease ([table 2b](#T2){ref-type="table"}). However with the Tg152c × Tg190 crosses, with a 6-fold excess of wild type PrP, transmissions were seen from all isolates, the majority resulting in clinical disease ([table 2b](#T2){ref-type="table"}).

To further investigate the effect of HuPrP V^127^ on prion propagation, we compared hemizygous Tg(HuPrP G^127^V^129^ *Prnp^o/o^*)-152c mice with the Tg152c × Tg183 and Tg152c × Tg190 crosses ([table 2c](#T2){ref-type="table"}). The hemizygous line was challenged with two classical CJD and one kuru isolate that had resulted in a 100% attack rate in both crosses. Again, 100% attack rates were seen for all three isolates but the incubation periods were significantly shorter (P\< 0.0001; [table 2c](#T2){ref-type="table"}) in the absence of HuPrP V^127^ than in either cross. These data, together with comparison of the two crosses themselves ([table 2b](#T2){ref-type="table"}), are consistent with a dominant negative effect of HuPrP V^127^ expression. Although dominant negative inhibition has been reported for other natural polymorphic residues of mammalian PrP in transgenic mice^[@R22]-[@R24]^ none have shown complete prevention of prion conversion when expressed at a 1:1 ratio with wild type PrP. Dominant negative effects on yeast prion propagation have also been reported^[@R25]^.

Our transgenic modelling of the HuPrP G127V polymorphism demonstrates that it confers strong protection against prion disease in the heterozygous state. However, most importantly, the molecular basis of this effect is clearly distinct from that proposed for the well-established HuPrP M129V polymorphism which is protective against developing sporadic CJD only in the heterozygous state: inhibition of homotypic protein-protein interactions during the process of prion propagation. Here we demonstrate that HuPrP V^127^ is intrinsically resistant to prion conversion and indeed capable of inhibiting propagation of wild type prions in a dose-dependent manner. Mice expressing only HuPrP V^127^ appear as resistant to prion disease as PrP null mice^[@R26]^ and understanding the structural basis of this effect may therefore provide critical insight into the molecular mechanism of mammalian prion propagation.

At its height when first recognised by Western medicine in 1957, kuru was a devastating epidemic largely affecting women and children and killing up to 2% of the population annually in some villages. Indeed some villages became largely devoid of young women of childbearing age. While collapse of the Fore population was prevented by cessation of endocannibalism in the late 1950s which interrupted the route of transmission and led to a gradual decline in incidence^[@R27]^, our data suggest that if transmission had continued the epicentre of the affected region might have been repopulated with kuru-resistant individuals as a population genetic response to the epidemic. Understanding the structural basis of why HuPrP V^127^ is unable to propagate prions of multiple strain types may provide key insights into prion propagation and the development of rational therapeutics.

Methods {#S1}
=======

Ethics Statement {#S2}
----------------

Storage and biochemical analyses of post-mortem human brain samples and transmission studies to mice were performed with written informed consent from patients with capacity to give consent. Where patients were unable to give informed consent, assent was obtained from their relatives in accordance with UK legislation and Codes of Practice. Samples were stored and used in accordance with the Human Tissue Authority Codes of Practice and in line with the requirements of the Human Tissue Authority licence held by UCL Institute of Neurology. This study was performed with approval from the Medical Research Advisory Committee of the Government of Papua New Guinea, the National Hospital for Neurology and Neurosurgery and the UCL Institute of Neurology Joint Research Ethics Committee (now National Research Ethics Service Committee, London -- Queen Square) - REC references: 03/N036, 03/N038 and 03/N133. Work with mice was performed under approval and licence granted by the UK Home Office (Animals (Scientific Procedures) Act 1986); Project Licence number 70/6454 which conformed to University College London institutional and ARRIVE guidelines ([www.nc3rs.org.uk/ARRIVE/](http://www.nc3rs.org.uk/ARRIVE/)).

Generation of transgenic mice {#S3}
-----------------------------

The 759bp human PrP ORF was amplified by PCR with pfu polymerase from genomic DNA prepared from the brain of a patient with the 127V polymorphism on the 129M allele, using forward primer 5′-[GTCGAC]{.ul}CAGTCATTATGGCGAACCTT-3′ and reverse primer 5′-[CTCGAG]{.ul}AAGACCTTCCTCATCCCACT-3′. Restriction sites Sal I and Xho I (underlined) were introduced in the forward and reverse primers respectively for cloning. The blunt ended PCR fragment generated by pfu polymerase was subcloned into Sma I digested pSP72 vector and sequenced to ensure that no spurious alterations had been introduced by the PCR and to confirm the presence of valine-127 and methionine-129 polymorphisms matching the patient DNA template. The amplified human PrP ORF with the confirmed polymorphisms was then isolated by Sal I and Xho I digestion. Subsequent subcloning into the Sal I site of the cosmid vector SHaCosTt, packaging and preparation of high quality DNA of the Not I transgene insert was as previously reported^[@R12]^. Microinjection of the purified Not I DNA fragment was carried out according to standard protocol into single cell eggs of *Prnp* null mice which had been backcrossed onto an FVB/N genetic background. Genotyping was performed by PCR and PrP expression levels estimated by western blot analysis as previously reported ^[@R12],\ [@R29]^. Two homozygous lines were established for variant HuPrP V^127^M^129^ described as Tg(HuPrP V^127^M^129^/V^127^M^129^ *Prnp^o/o^*)-183 (V^127^M^129^ Tg183) and Tg(HuPrP V^127^M^129^/V^127^M^129^ *Prnp^o/o^*)-190 (V^127^M^129^ Tg190), with transgene expression levels of 2 and 1 × respectively, that of pooled 10% (w/v) normal human brain homogenate ([table 1](#T1){ref-type="table"}). FVB-congenic versions of Tg35 mice homozygous for HuPrP G^127^M^129^ ^[@R12]-[@R15]^ and Tg152 mice homozygous for HuPrP G^127^V^129^ ^[@R15]-[@R19]^ were used as wild type human PrP-expressing controls, designated Tg(HuPrP G^127^M^129^/G^127^M^129^ *Prnp^o/o^*)-35c (G^127^M^129^ Tg35c) and Tg(HuPrP G^127^V^129^/G^127^V^129^ *Prnp^o/o^*)-152c (G^127^V^129^ Tg152c) respectively. The *PRNP* codon 127-129 genotypes and relative expression levels of wild type and variant PrP in the parental transgenic lines and in the F1 crosses are shown in [table 1](#T1){ref-type="table"}.

Transmission Studies {#S4}
--------------------

Strict bio-safety protocols were followed. Inocula were prepared, using disposable equipment for each inoculum, in a microbiological containment level 3 laboratory and inoculations performed within a class 1 microbiological safety cabinet as described previously^[@R12],\ [@R19]^. Ten mice per group of control G^127^M^129^ Tg35c and G^127^V^129^ Tg152c lines and 15 per group of newly generated V^127^M^129^ Tg183, V^127^M^129^ Tg190 lines and their respective crosses with Tg35c and Tg152c, were inoculated (see below) with human brain homogenates from neuropathologically confirmed patients comprising, four kuru cases, eight sporadic CJD cases, four iatrogenic CJD cases and two cases of vCJD. The genotype of each mouse was confirmed by PCR of ear punch DNA prior to inclusion and all mice were uniquely identified by sub-cutaneous transponders. Disposable cages were used and all cage lids and water bottles were also uniquely identified by transponder and remained with each cage of mice throughout the incubation period. Care of the mice was according to institutional guidelines. Mice (female, aged 6-8 weeks) were randomly assigned to experimental groups and anaesthetised with a mixture of halothane and O~2~, and intracerebrally inoculated into the right parietal lobe with 30 μl of a 1% (w/v) brain homogenate prepared in Dulbecco's phosphate buffered saline lacking Ca^2+^ or Mg^2+^ ions (D-PBS). All mice were thereafter examined daily for early indicators of clinical prion disease including piloerection, sustained erect ears, intermittent generalised tremor, unsustained hunched posture, rigid tail, mild loss of coordination,and clasping hind legs when lifted by the tail. Definite diagnosis of clinical prion disease (triggering experimental end point) was reached if mice exhibited any two early indicator signs in addition to one confirmatory sign, or any two confirmatory signs. The confirmatory signs included ataxia,impairment of righting reflex, dragging of hind limbs, sustained hunched posture, or significant abnormal breathing. Mice were killed (by CO~2~ asphyxiation) if they exhibited any signs of distress or once a diagnosis of prion disease was established. At post-mortem brains from inoculated mice were removed, divided sagittally with half frozen and half fixed in 10% buffered formol saline. Subsequent immunohistochemical or biochemical investigations were performed blind to sample provenance.

Neuropathology and Immunohistochemistry {#S5}
---------------------------------------

Fixed brain was immersed in 98% formic acid for 1 hour and paraffin wax embedded. Serial sections of 4 μm thickness were pre-treated by boiling for 10 min in a low ionic strength buffer (2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8) before exposure to 98% formic acid for 5 min. Abnormal PrP accumulation was examined using anti-PrP monoclonal antibody ICSM 35 (D-Gen Ltd, London) on a Ventana automated immunohistochemical staining machine (Ventana Medical Systems Inc., Tucson, Arizona) using proprietary secondary detection reagents (Ventana Medical Systems Inc) before development with 3′3 diaminobenzedine tetrachloride as the chromogen^[@R30]^. Harris haematoxylin and eosin staining was done by conventional methods. Appropriate controls were used throughout.

Immunoblotting {#S6}
--------------

Preparation of brain homogenates (10% (w/v) in D-PBS), proteinase K digestion (75 μg/ml for 1 h at 37°C) and subsequent immunoblotting was performed as described previously^[@R28],\ [@R30]^. Blots were probed with anti-PrP monoclonal antibody ICSM 35 (D-Gen Ltd, London) in conjunction with an anti-mouse IgG-alkaline phosphatase conjugate and development in chemiluminescent substrate (CDP-Star; Tropix Inc). Primary screening of brain homogenates was performed blind to sample identity.

Extended Data {#S7}
=============

![Immunoblots showing relative PrP^C^ expression levels in transgenic mice\
The provenance of each brain sample is designated above each lane and molecular markers are indicated on the left. The *PRNP* codon 127 (G, glycine, V, valine) or codon 129 (M, methionine, V, valine) genotypes of the transgenic mice are designated below. Transgenic mouse brains were analysed by enhanced chemiluminescence without proteinase-K digestion and equal amounts of total protein loaded in each well and probed with anti-PrP monoclonal antibody ICSM 35. Wild type human PrP expression levels of G^127^M^129^/G^127^M^129^ Tg35c and G^127^V^129^/G^127^V^129^ Tg152c mice are 2- and 6-fold higher respectively, than seen in 10 % (w/v) pooled human brain homogenate. Homozygous V^127^M^129^ Tg183 and Tg190 mice have 2-fold higher or equivalent PrP expression levels respectively compared to 10 % (w/v) pooled human brain homogenate.](emss-63379-f0001){#F2}

![Immunohistochemical analysis of transgenic mouse brain following challenge with vCJD prions\
All mice were intracerebrally challenged with the same vCJD prion isolates (I342 and I7042). Abnormal PrP deposition in fixed post-mortem brain from affected mice was detected using anti-PrP monoclonal antibody ICSM 35. (a-b) Homozygous Tg35c mice (expressing G^127^M^129^/G^127^M^129^ wild type PrP only) show intense and widespread PrP plaque deposits. Magnified areas show (ai) hippocampus, (bi) frontal cortex and (aii and bii) thalamus. In contrast, heterozygous G^127^M^129^/V^127^M^129^ Tg35c/Tg183 mice expressing equivalent levels of G^127^M^129^ and V^127^M^129^ PrP (c*-d*) show only weak PrP deposition in the corpus callosum (ci and di) with no abnormal PrP deposition detected in other brain areas, for example, in the thalamus (cii and dii). Heterozygous G^127^M^129^/V^127^M^129^ Tg35c/Tg190 mice which express a lower level of V^127^M^129^ PrP relative to wild type G^127^M^129^ PrP (e-f) show greater levels of PrP deposition than seen in Tg35c/Tg183 mice following challenge with the same vCJD prion isolates, (ei, eii and fi) corpus callosum; (fii) pons. Scale bar, upper panels (a-f) 2 mm; magnified panels, 100 μm.](emss-63379-f0002){#F3}

![Immunohistochemical analysis of homozygous *PRNP* V^127^M^129^/V^127^M^129^ transgenic mouse brain following challenge with human prions\
Mice were intracerebrally challenged with kuru, classical and variant CJD prions. Following prolonged (\>600 days) post inoculation periods, abnormal PrP deposition in fixed post-mortem brain was examined using anti-PrP monoclonal antibody ICSM 35. (a-d) V^127^M^129^/V^127^M^129^ Tg183 mice with 2-fold overexpression of V^127^M^129^ PrP. (*E-H*) V^127^M^129^/V^127^M^129^ Tg190 mice expressing endogenous levels of V^127^M^129^ PrP. Red square boxes in the main panels (a-h) define the area of magnified images of hippocampus (i) and thalamus (ii) shown in the lower panels. Scale bar, a-h, 2 mm; magnified panels i and ii, 100 μm. The lack of detection of abnormal PrP deposition in brain indicates that the mice are not subclinically infected with prions.](emss-63379-f0003){#F4}

![Schematic diagram summarising transmissions of kuru and classical CJD prions to transgenic mice expressing human PrP\
G^127^M^129^/G^127^M^129^ Tg35c mice or G^127^V^129^/G^127^V^129^ Tg152c mice are homozygous for wild type human PrP alleles and are fully susceptible to kuru and classical CJD prions. V^127^M^129^/V^127^M^129^ Tg183 or V^127^M^129^/V^127^M^129^ Tg190 transgenic mice are homozygous for the variant V^127^M^129^ allele found only in humans from the kuru-exposed population of Papua New Guinea and are entirely resistant to infection with kuru and classical CJD prions. The levels of PrP expression in the brain of these homozygous transgenic mice relative to a pooled human brain homogenate are 1× (Tg190 mice) 2× (Tg35c and Tg183 mice) and 6× (Tg152c mice). Generation of F1 mice through inter-breeding the various homozygous lines produces different combinations of the various human PrP alleles leading to differences in the relative expression levels of the various prion proteins in brain. The PrP expression ratios from the two PrP alleles in the crosses are shown in parentheses above the cartoon mice. Full, intermediate or low susceptibility of the mice to infection with kuru and classical CJD prions is indicated by three, two or one diagonal red bar, respectively, drawn across the mice. Mice with no red bar are entirely resistant to infection with kuru and classical CJD prions.](emss-63379-f0004){#F5}

![Immunohistochemical analysis of homozygous *PRNP* G^127^V^129^/G^127^V^129^ and heterozygous G^127^V^129^/V^127^M^129^ transgenic mouse brain following challenge with human prions\
Mice were intracerebrally challenged with kuru and classical CJD prions and abnormal PrP deposition in fixed post-mortem brain from affected mice was examined using anti-PrP monoclonal antibody ICSM 35. Red square boxes labelled i and ii in panels a-f mark brain areas that are magnified and displayed below; (i) cortex and (ii) thalamus. (a-b) Wild type G^127^V^129^/G^127^V^129^ Tg152c mice. (c-d) Heterozygous G^127^V^129^/V^127^M^129^ Tg152c/Tg183 mice. (e-f) Heterozygous G^127^V^129^/V^127^M^129^ Tg152c/190 mice Scale bar, a-f, 2 mm; magnified panels i and ii, 100 μm. The detection of abnormal PrP deposition in brain indicates that the mice are infected with prions.](emss-63379-f0005){#F6}
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![Transmission rates of human prions to transgenic mice homo- or heterozygous for human PrP V^127^\
Transgenic mice were intracerebrally inoculated with brain homogenate from patients with kuru (a) or classical CJD (b). Codon 127 and 129 *PRNP* genotypes of the recipient mice are shown (G, glycine, M, methionine, V, valine). G^127^M^129^ is a wild type human allele, and the V^127^M^129^ allele is seen only in humans from the kuru-exposed population of Papua New Guinea. Attack rate reports the total of clinically affected and sub-clinically infected mice as a proportion of the number of inoculated mice after prolonged (\>600 days) post-inoculation periods. Primary prion transmission data are reported in [tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.](emss-63379-f0006){#F1}

###### Transgenic mice expressing G^127^ and V^127^ human PrP

  Transgenic mice                                        *PRNP* Codon 127-129 genotype   Total HuPrP[\*](#TFN1){ref-type="table-fn"} expression level (x)   WT^[†](#TFN2){ref-type="table-fn"}^ G^127^ allele expression level (x)   Variant^[‡](#TFN3){ref-type="table-fn"}^ V^127^ allele expression level (x)   PrP Ratio G^127^ : V^127^
  ------------------------------------------------------ ------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------ ----------------------------------------------------------------------------- ---------------------------
  **Parental lines:**                                                                                                                                                                                                                                                                                              
  Tg35c                                                  G^127^M^129^/G^127^M^129^       2                                                                  2                                                                        \-                                                                            \-
  Tg152c                                                 G^127^V^129^/G^127^V^129^       6                                                                  6                                                                        \-                                                                            \-
  Tg183                                                  V^127^M^129^/V^127^M^129^       2                                                                  \-                                                                       2                                                                             \-
  Tg190                                                  V^127^M^129^/V^127^M^129^       1                                                                  \-                                                                       1                                                                             \-
  **F1 crosses:**                                                                                                                                                                                                                                                                                                  
  Tg35c × Tg183                                          G^127^M^129^/V^127^M^129^       2                                                                  1                                                                        1                                                                             1 : 1
  Tg35c × Tg190                                          G^127^M^129^/V^127^M^129^       1.5                                                                1                                                                        0.5                                                                           2 : 1
  Tg152c × Tg183                                         G^127^V^129^/V^127^M^129^       4                                                                  3                                                                        1                                                                             3 : 1
  Tg152c × Tg190                                         G^127^V^129^/V^127^M^129^       3.5                                                                3                                                                        0.5                                                                           6 : 1
  Tg152c ^+/o^ (Hemi)^[§](#TFN4){ref-type="table-fn"}^   G^127^V^129^                    3                                                                  3                                                                        \-                                                                            \-

WT = wild type

PrP expression level is relative to pooled 10% (w/v) normal human brain homogenate

Wild type alleles are either G^127^M^129^ or G^127^V^129^

Variant allele is V^127^M^129^

Generated by crossing Tg152c with FVB/PrP-null mice

###### Transmission of human prions to transgenic mice heterozygous for human PrP V^127^

  Inoculum    Transmission data                                                             
  ----------- ------------------- ------- ------- --------------- ------ ----------- ------ -----------
  kuru        I516                T3 VV   14/14   509 ± 56 (3)    0/11   \>518-605   0/13   \>517-605
  kuru        I520                T3 VV   12/12   558 ± 4 (4)     0/14   \>525-622   0/14   \>460-622
  kuru        I10336              T3 MV   13/13   454 ± 14 (10)   0/14   \>522-606   0/11   \>504-607
  kuru        I518                T2 MM   11/11   493 ± 32 (7)    0/12   \>545-620   0/13   \>544-603
  iCJD (GH)   I035                T1 MM   10/10   221 ± 3 (10)    0/10   \>462-603   0/8    \>506-602
  sCJD        I11058              T1 MM   8/8     231 ± 3 (8)     0/8    \>467-605   0/7    \>487-605
  iCJD (DM)   I026                T2 MM   10/10   256 ± 9 (8)     0/8    \>507-601   0/7    \>520-602
  sCJD        I7040               T2 MM   10/10   233 ± 3 (10)    0/8    \>582-604   0/7    \>600-604

  **B**                        Tg152c G^127^V^129^/G^127^V^129^   Tg152c × Tg183 G^127^V^129^/V^127^M^129^   Tg152c × Tg190 G^127^V^129^/V^127^M^129^                          
  ----------- -------- ------- ---------------------------------- ------------------------------------------ ------------------------------------------ -------------- ------- --------------
  kuru        I516     T3 VV   9/9                                218 ± 1 (6)                                0/13                                       \>447-608      9/15    543, 592
  kuru        I520     T3 VV   9/9                                196 ± 7 (7)                                0/18                                       \>491-616      13/13   498 ± 17 (5)
  kuru        I10336   T3 MV   15/15                              212 ± 3 (11)                               15/15                                      456 ± 3 (15)   15/15   316 ± 4 (14)
  kuru        I518     T2 MM   11/11                              211 ± 4 (8)                                3/11                                       \>494-620      13/14   468 ± 13 (9)
  sCJD        I280     T2 VV   8/8                                203 ± 5 (4)                                0/4                                        \>600-602      10/10   559 ± 14 (8)
  sCJD        I278     T2 VV   6/6                                236 ± 8 (6)                                0/8                                        \>424-602      8/9     582
  sCJD        I284     T2 MV   9/9                                338 ± 4 (8)                                0/9                                        \>410-602      5/7     \>545-608
  sCJD        I1478    T2 MV   10/10                              248 ± 8 (8)                                0/6                                        \>451-608      2/7     \>482-603
  sCJD        I7394    T3 VV   9/9                                213 ± 1 (8)                                7/7                                        \>537-677      10/10   427 ± 8 (10)
  sCJD        I764     T3 MV   10/10                              219 ± 5 (7)                                9/10                                       \>368-588      10/10   461 ± 7 (9)
  iCJD (GH)   I2651    T3 VV   8/8                                200 ± 3 (6)                                0/6                                        \>567-607      7/7     538 ± 2 (5)
  iCJD (GH)   I020     T3 MV   9/9                                211 ± 2 (6)                                7/7                                        \>489-602      10/10   399 ± 8 (9)

  **C**                        Tg152c × Tg183 G^127^V^129^/V^127^M^129^   Tg152c × Tg190 G^127^V^129^/V^127^M^129^   Tg152c+/o (Hemi) G^127^V^129^                                                           
  ----------- -------- ------- ------------------------------------------ ------------------------------------------ ------------------------------- ----------------------------------------------- ------- -----------------------------------------------
  iCJD (GH)   I020     T3 MV   7/7                                        \>489-602                                  10/10                           399 ± 8^[‡](#TFN7){ref-type="table-fn"}^ (9)    14/14   252 ± 3^[‡](#TFN7){ref-type="table-fn"}^ (14)
  sCJD        I7394    T3 VV   7/7                                        \>537-677                                  10/10                           427 ± 8^[‡](#TFN7){ref-type="table-fn"}^ (10)   12/12   245 ± 5^[‡](#TFN7){ref-type="table-fn"}^ (12)
  kuru        I10336   T3 MV   15/15                                      456 ± 3 (15)                               15/15                           316 ± 4^[‡](#TFN7){ref-type="table-fn"}^ (14)   15/15   222 ± 2^[‡](#TFN7){ref-type="table-fn"}^ (15)

  **D**                   Tg35c G^127^M^129^/G^127^M^129^   Tg35c × Tg183 G^127^M^129^/V^127^M^129^   Tg35c × Tg190 G^127^M^129^/V^127^M^129^                       
  ------- ------- ------- --------------------------------- ----------------------------------------- ----------------------------------------- ----------- ------- ------------
  vCJD    I342    T4 MM   15/15                             \>426-603                                 9/15                                      467, 556    17/18   419±17 (3)
  vCJD    I7042   T4 MM   14/14                             559, 561                                  4/13                                      \>496-607   10/12   596

iCJD, iatrogenic CJD; sCJD, sporadic CJD; GH, growth hormone; DM, dura mater

According to classification of Hill et al.^[@R28]^

Attack rate is defined as the total number of both clinically *affected* and sub-clinically *infected* mice as a proportion of the total number of *inoculated* mice. Sub-clinical prion infection was assessed by immunoblotting and/or immunohistochemical examination of brain. Incubation periods are reported for clinically affected mice in days; where n ≥ 3 the mean ± SEM is reported with the number of mice contributing to the mean shown in parentheses, otherwise individual incubation times are given. In groups where no clinical transmission of prion disease was observed, the attack rate represents subclinical infection only and the interval between inoculation and death (from either senescence, culling due to inter-current illness or termination of the experiment) is reported as \>x-y days.

Mean incubation periods for all 3 isolates are significantly lower in Tg152c hemizygotes than in Tg190 × Tg152c heterozygotes (P\<0.0001; two-tailed unpaired t-test).

###### Transmission of human prions to transgenic mice homozygous for human PrP V^127^

  Inoculum    Transmission data                                                                                                      
  ----------- ------------------- ------- ----------------------------------------- ----------------------------------------- ------ -----------
                                          **Tg183** **V^127^M^129^/V^127^M^129^**   **Tg190** **V^127^M^129^/V^127^M^129^**          
  kuru        I516                T3 VV   0/19                                      \>488-604                                 0/22   \>391-609
  kuru        I520                T3 VV   0/19                                      \>391-609                                 0/19   \>370-609
  kuru        I10336              T3 MV   0/21                                      \>405-607                                 0/24   \>463-617
  kuru        I518                T2 MM   0/12                                      \>439-600                                 0/13   \>432-603
  vCJD        I342                T4 MM   0/8                                       \>553-605                                 0/10   \>506-604
  vCJD        I7042               T4 MM   0/11                                      \>522-609                                 0/14   \>446-607
  iCJD (GH)   I035                T1 MM   0/10                                      \>434-622                                 0/10   \>450-602
  sCJD        I11058              T1 MM   0/8                                       \>411-609                                 0/9    \>454-612
  iCJD (DM)   I026                T2 MM   0/9                                       \>381-602                                 0/8    \>516-602
  sCJD        I7040               T2 MM   0/8                                       \>524-601                                 0/6    \>564-600
  sCJD        I280                T2 VV   0/9                                       \>532-602                                 0/9    \>425-601
  sCJD        I278                T2 VV   0/7                                       \>530-602                                 0/7    \>417-601
  sCJD        I284                T2 MV   0/6                                       \>549-603                                 0/6    \>466-609
  sCJD        I1478               T2 MV   0/7                                       \>517-602                                 0/7    \>418-617
  sCJD        I7394               T3 VV   0/8                                       \>500-600                                 0/8    \>600-603
  sCJD        I764                T3 MV   0/10                                      \>447-602                                 0/8    \>484-607
  iCJD (GH)   I2651               T3 VV   0/7                                       \>563-606                                 0/7    \>487-599
  iCJD (GH)   I020                T3 MV   0/6                                       \>546-603                                 0/6    \>572-600

(days p.i), days post inoculation; vCJD, variant CJD; sCJD, sporadic CJD; iCJD, iatrogenic CJD; GH, growth hormone; DM, dura mater

According to classification of Hill et al.^[@R28]^

Attack rate is defined as the total of clinically *affected* and sub-clinically *infected* mice as a proportion of the number of *inoculated* mice. Sub-clinical prion infection was assessed by immunoblotting and/or immunohistochemical examination of brain. As no clinical transmission of prion disease was observed the interval between inoculation and death (from either senescence, culling due to inter-current illness or termination of the experiment) is reported as \>x-y days.
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